Effects of Anxiety on Coronary Microcirculatory Function in Hypertensive Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Lijun Guo
- Phone Number: +8682265018
- Email: guo_li_jun@126.com
Study Contact Backup
- Name: Ying Li
- Phone Number: 18811735238
- Email: liying_winter@163.com
Study Locations
-
-
-
Beijing, China, 100191
- Recruiting
- Peking University Third Hospital
-
Contact:
- Ying Li
- Phone Number: 18811735238
- Email: liying_winter@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with clear diagnosis of hypertension (≥1 year, drug control within 140/90mmHg); (2) Significant coronary artery stenosis was excluded by imaging within 1 year (≤50%); (3) Age between 18 and 80.
Exclusion Criteria:
- CHD, heart valve disease, congenital heart disease, cardiomyopathy and pericardial disease; (2) Left ventricular ejection fraction (LVEF) <50%; (3) Increased markers of myocardial injury; (4) Diabetes mellitus, connective tissue disease, chronic obstructive pulmonary disease and malignant tumor; 5) Severe hepatic and renal impairment (Cr ≥120 umol/L, ALT ≥120 umol/L); 6) Pregnant women.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
anxiety group
the score of Self-rating Anxiety Scale greater than 50
|
Coronary flow velocity profiles in the left anterior descending artery were obtained using colour-guided pulse wave Doppler.
We measured peak diastolic coronary flow velocity of the diastolic coronary waveform at rest and after ATP infusion (140 µg/kg.
min) for 2 min.
The CFR was calculated as the ratio of hyperaemic peak diastolic velocity to resting baseline diastolic velocity.
All patients abstained from caffeine-containing drinks for at least 24h before testing.
|
|
non-anxiety group
the score of Self-rating Anxiety Scale less than 50
|
Coronary flow velocity profiles in the left anterior descending artery were obtained using colour-guided pulse wave Doppler.
We measured peak diastolic coronary flow velocity of the diastolic coronary waveform at rest and after ATP infusion (140 µg/kg.
min) for 2 min.
The CFR was calculated as the ratio of hyperaemic peak diastolic velocity to resting baseline diastolic velocity.
All patients abstained from caffeine-containing drinks for at least 24h before testing.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Coronary flow reserve
Time Frame: baseline
|
Coronary flow reserve (CFR) is an integrated measure of flow through both the large epicardial arteries and the coronary microcirculation.
In the absence of obstructive stenosis of the epicardial arteries, CFR is an index of coronary microcirculatory function.
|
baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Inflammatory mediators
Time Frame: baseline
|
Inflammatory mediators were measured using Quantibody Human Immune Response Array.
|
baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Lijun Guo, Peking University Third Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- M2018058
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.